Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xtant Medical Holdings ( (XTNT) ) just unveiled an announcement.
On December 1, 2025, Xtant Medical Holdings completed the sale of its Coflex and CoFix product assets and its shares in Paradigm Spine GmbH to Companion Spine, LLC, and Companion Spine SAS for a total of $19.2 million. This divestiture, which includes a mix of cash payments and an unsecured promissory note, is part of a strategic move to streamline operations and reduce debt, as $8 million of the proceeds were used to prepay a portion of the company’s term loan with MidCap Financial Trust.
The most recent analyst rating on (XTNT) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page.
Spark’s Take on XTNT Stock
According to Spark, TipRanks’ AI Analyst, XTNT is a Neutral.
Xtant Medical Holdings is on a recovery path with strong revenue growth and improving financial metrics. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The positive outlook from the earnings call, including strategic initiatives and asset sales, supports future growth prospects.
To see Spark’s full report on XTNT stock, click here.
More about Xtant Medical Holdings
Xtant Medical Holdings, Inc. operates in the medical industry, focusing on the development and commercialization of regenerative medicine products and medical devices. The company is known for its products related to spinal surgery and other orthopedic applications.
Average Trading Volume: 248,642
Technical Sentiment Signal: Strong Sell
Current Market Cap: $84.18M
See more data about XTNT stock on TipRanks’ Stock Analysis page.